Drug Trial Radar · NCT07066826
Clinical Study to Evaluate the Efficacy and Safety of Huperzine A Controlled-Release Tablets in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
Last checked: Nov 20, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
720
Planned (sponsor's estimate)
Start
Aug 29, 2025
Primary completion
Aug 15, 2028
Study completion Aug 15, 2028
Sponsor
- Lead sponsor
- Wanbangde Pharmaceutical Group Co., LTDIndustry
- Sponsor type
- Industry
- First posted
- Jul 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, randomized, double-blind, double-dummy, active- and placebo-controlled, parallel-group clinical trial. The dose confirmation stage is designed to evaluate the efficacy and safety of different doses of huperzine A controlled-release tablets in patients with mild-to-moderate dementia of the Alzheimer's type, with the goal of providing a basis for dose selection in the subsequent efficacy confirmation stage. The efficacy confirmation stage aims to assess the effect of huperzine A controlled-release tablets on cognitive function and functional abilities in patients with mild-to-moderate dementia of the Alzheimer's type.In the open-label extension stage, all subjects will receive huperzine A controlled-release tablets until Week 52, to further evaluate the long-term efficacy and safety of the treatment.
Conditions
- Alzheimer Dementia
Interventions
Huperzine A Controlled-Release TabletsDrug
During the trial, the patients should take huperzine A controlled-release tablets in the morning
Donepezil hydrochloride tabletsDrug
During the trial, the patients should take donepezil hydrochloride tablets before going to bed in the evening
Huperzine A controlled-release tablets placebo; Donepezil hydrochloride tablets placeboDrug
During the trial, the patients should take huperzine A controlled-release tablets placebo in the morning and donepezil hydrochloride tablets placebo before going to bed in the evening
Primary outcomes
What the sponsor says the trial is designed to measure.
- ADAS-Cog11Time frame: week24
- ADCS-ADLTime frame: week24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Xuanwu Hospital Capital Medical University
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.